GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Mirum Pharmaceuticals
Mirum Pharmaceuticals specializes in treating rare pediatric liver diseases. Its stock price reflects the success of its drug commercialization. This chart illustrates how addressing an unmet medical need in a niche market can generate significant value.
Share prices of companies in the market segment - Pharma liver
Mirum Pharmaceuticals specializes in treating rare pediatric liver diseases. We classify the company as part of the Pharma Liver sector, and the chart below reflects the overall dynamics of this market segment.
Broad Market Index - GURU.Markets
Mirum Pharmaceuticals is a biopharmaceutical company focused on developing treatments for rare liver diseases in children and adults. As a component of the GURU.Markets index, it represents the orphan disease sector. The chart below represents the entire market. See how Mirum shares compare to the overall trend.
Change in the price of a company, segment, and market as a whole per day
MIRM - Daily change in the company's share price Mirum Pharmaceuticals
The price movement of Mirum Pharmaceuticals, a biopharmaceutical company focused on rare liver diseases, reflects the sector's high volatility. Change_co measures sensitivity to clinical trial news. This metric is key to analyzing biotech risks on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma liver
Mirum Pharmaceuticals, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with MIRM, which focuses on rare liver diseases, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Mirum Pharmaceuticals is a biopharmaceutical company specializing in drugs for the treatment of rare liver diseases. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing Mirum's stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Mirum Pharmaceuticals
Mirum Pharmaceuticals is a biotech company specializing in the treatment of liver diseases. Its shares move in sync with news about clinical trials. This high, event-driven volatility feeds into the overall market flow.
Annual dynamics of market capitalization of the market segment - Pharma liver
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the treatment of rare liver diseases. Its success depends on the commercialization of its approved drugs and the results of its R&D. The chart below shows how its focus on this complex and important medical niche influences its performance in the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Mirum Pharmaceuticals is a biotech company whose future depends on the success of its drugs for rare liver diseases. Its stock price is completely disconnected from economic cycles. The company's chart is a story of scientific breakthroughs, clinical trials, and regulatory decisions, not macroeconomic news.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Mirum Pharmaceuticals
Mirum, a biopharmaceutical company, depends on its commercial success for its market value. The monthly fluctuations on the chart reflect sales data for its drugs for treating rare pediatric liver diseases, as well as news about clinical trials that could expand their use.
Monthly dynamics of market capitalization of the market segment - Pharma liver
Mirum Pharmaceuticals specializes in developing drugs to treat rare liver diseases, particularly in children. This is a narrow but critically important niche in the pharmaceutical industry. The chart below illustrates the overall dynamics of the biotech sector, where the success or failure of a single drug's clinical trials can dramatically alter a company's fortunes.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Shares of biotech companies specializing in rare liver diseases often move on news about their drugs. The chart below shows general market trends. Does Mirum Pharmaceuticals have a life of its own, or does its commercial status make it more closely correlated with the market?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Mirum Pharmaceuticals
Mirum Pharmaceuticals, which focuses on treating rare liver diseases, belongs to the high-risk biotech sector. Its weekly stock price is a direct response to news about clinical trials, regulatory decisions on its drugs, and sales reports, which creates significant price fluctuations.
Weekly dynamics of market capitalization of the market segment - Pharma liver
Biotech companies focused on rare liver diseases, like Mirum, are driven by news of clinical trials. The success or failure of one player often impacts the entire niche. The chart below shows this overall pulse. It allows one to assess how promising the market perceives Mirum's technology compared to competitors' developments.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Mirum Pharmaceuticals specializes in drugs for rare liver diseases. It's a niche market where the success of a single drug can dramatically change the company's fortunes. This chart shows how its stock is performing in its own world, responding to research data rather than market sentiment.
Market capitalization of the company, segment and market as a whole
MIRM - Market capitalization of the company Mirum Pharmaceuticals
Mirum Pharmaceuticals' market capitalization reflects investors' assessment of its focus on treating rare pediatric liver diseases. Its dynamics are directly dependent on successful sales of approved drugs and progress in clinical trials. Its scale reflects the market's potential appreciation for drugs for orphan (rare) diseases.
MIRM - Share of the company's market capitalization Mirum Pharmaceuticals within the market segment - Pharma liver
Mirum Pharmaceuticals specializes in the treatment of rare liver diseases, holding a leading market share in this narrow but important niche. Its market capitalization reflects the success of its drugs, which offer new options for patients with limited treatment options.
Market capitalization of the market segment - Pharma liver
Below is a chart showing the combined weight of the entire biotech sector focused on rare liver diseases. For Mirum Pharmaceuticals, which specializes in treating pediatric cholestatic diseases, this line represents the size of the potential reward. The rising chart reflects investors' belief that effective treatments can be found even for rare diseases.
Market capitalization of all companies included in a broad market index - GURU.Markets
Mirum Pharmaceuticals specializes in treating rare liver diseases. Its market cap, like that of many biotech companies, is a bet on the success of its drugs. Globally, this represents the stake investors are willing to invest in finding solutions for poorly understood diseases.
Book value capitalization of the company, segment and market as a whole
MIRM - Book value capitalization of the company Mirum Pharmaceuticals
Mirum Pharmaceuticals develops drugs to treat rare liver diseases. Its book value reflects the resources it supports this mission: R&D laboratories, patents, and manufacturing agreements. This is the foundation for creating life-saving medicines. How has this scientific and financial capital grown? The chart below shows its development.
MIRM - Share of the company's book capitalization Mirum Pharmaceuticals within the market segment - Pharma liver
Mirum Pharmaceuticals specializes in rare liver diseases, and its developments are supported by a strong infrastructure. These include research laboratories and manufacturing facilities that meet strict standards for the production of orphan drugs. The chart shows the company's share of physical infrastructure for this niche pharmaceutical segment.
Market segment balance sheet capitalization - Pharma liver
Mirum Pharmaceuticals focuses on treating rare liver diseases. Pharmaceuticals, as the chart shows, are both knowledge- and capital-intensive. As a commercial company, Mirum invests not only in R&D but also in the infrastructure for sales and marketing of its drugs.
Book value of all companies included in the broad market index - GURU.Markets
Mirum Pharmaceuticals develops drugs for rare liver diseases based on scientific research. The company's book value is represented by its research centers, laboratories, and capital for clinical trials. The chart shows the material foundation on which hope for patients with orphan diseases is built.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Mirum Pharmaceuticals
Mirum Pharma's balance sheet is used for research. But the market sees a potential blockbuster for the treatment of rare liver diseases. The chart shows the enormous "hope factor" that investors are factoring into the price, valuing the drug's future sales at hundreds of times its current assets.
Market to book capitalization ratio in a market segment - Pharma liver
Mirum Pharmaceuticals specializes in drugs for rare liver diseases. Like many biotech companies, its valuation is based on the potential of its drugs. This chart clearly demonstrates how much investor expectations for future sales exceed the company's current operating capital.
Market to book capitalization ratio for the market as a whole
Mirum Pharmaceuticals specializes in developing drugs to treat rare liver diseases in children and adults. The company's main assets are its drug portfolio and research. This chart shows the overall market valuation, but how do investors value biotech companies aimed at helping patients with orphan (rare) diseases?
Debts of the company, segment and market as a whole
MIRM - Company debts Mirum Pharmaceuticals
For Mirum, a pharmaceutical company with existing drugs on the market, debt may be preferable to issuing equity. It allows for funding the global launch of sales and further research without diluting the stakes of current shareholders. This is a strategy for leveraging success to finance future growth.
Market segment debts - Pharma liver
Mirum Pharmaceuticals specializes in developing drugs for rare liver diseases. Focusing on orphan drugs can be highly profitable, but it requires significant investment in high-risk research. This chart shows how the company funds its clinical programs compared to other biotech companies.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Mirum Pharmaceuticals
Mirum Pharmaceuticals specializes in developing drugs for rare liver diseases. This chart shows the company's financial structure at the commercialization stage. After receiving approval for its first drug, debt management becomes critical to funding sales launches, marketing, and continuing research in other areas.
Market segment debt to market segment book capitalization - Pharma liver
Developing drugs for rare liver diseases, Mirum's focus, is a high-risk, high-reward business. This chart shows how the biotech sector as a whole funds its research and development. It allows one to assess how reliant Mirum's financial model is on external capital to conduct expensive clinical trials compared to the industry.
Debt to book value of all companies in the market
This chart shows the average debt burden across the entire economy. Mirum, a biotech company developing drugs for rare diseases, relies on investments for its finances. Comparison with the overall market, comprised of profitable businesses, clearly demonstrates how different a financial model based on science, rather than sales, is from traditional economics.
P/E of the company, segment and market as a whole
P/E - Mirum Pharmaceuticals
This chart for Mirum Pharmaceuticals, which specializes in treating rare liver diseases, illustrates the lofty expectations of investors. Like many biotechs, its value is based on the potential of its drugs to become standard treatments in their niches. This is a reward for future revenue from drugs that could change patients' lives.
P/E of the market segment - Pharma liver
Mirum's specialty, treating rare liver diseases, is a niche with high potential. This chart shows the average valuation for biopharmaceutical companies. It helps understand how investors assess the commercial success of Mirum's already approved drugs and its potential to become a leader in its narrow but important field.
P/E of the market as a whole
Mirum Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing drugs to treat rare liver diseases, particularly in children. This chart reflects the overall risk appetite of investors in biotech. It helps understand whether MIRM's valuation is based on confidence in the potential of its rare disease drugs or whether it moves in line with overall sector sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Mirum Pharmaceuticals
Mirum Pharmaceuticals specializes in developing drugs to treat rare liver diseases, particularly in children. This chart reflects investors' high expectations for the commercial success of its drugs. Its dynamics reflect the market's assessment of potential demand for drugs for orphan diseases, which are often highly priced and face limited competition.
%20P%2FE%20Mirum%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Mirum-Pharmaceuticals&v=1772513805094 "Chart of the company's future (projected) P/E Mirum Pharmaceuticals")
Future (projected) P/E of the market segment - Pharma liver
Mirum Pharmaceuticals specializes in developing and commercializing drugs to treat rare liver diseases in children and adults. This chart shows how its future revenue expectations compare to the biopharmaceutical sector average. Does the market appreciate the potential of its drugs to transform the lives of patients in underserved niches?
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-liver&v=1772513805099 "Future (projected) P/E graph of the market segment - Pharma liver")
Future (projected) P/E of the market as a whole
Mirum Pharmaceuticals specializes in treating rare pediatric liver diseases. Demand for its drugs is inelastic and unaffected by economic cycles, as it aims to save lives. Therefore, the company's valuation is determined by its success in drug development and commercialization, rather than by general market expectations, as reflected in the chart.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513805116 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Mirum Pharmaceuticals
Mirum Pharmaceuticals specializes in developing drugs to treat rare liver diseases in children and adults. The company's profitability depends on the success of its commercialized products and progress in clinical trials. This graph shows the company's journey from an unprofitable R&D company to a potentially profitable player in the orphan disease niche.
Profit of companies in the market segment - Pharma liver
Mirum Pharmaceuticals specializes in developing drugs to treat rare liver diseases, particularly in children. The company occupies a narrow but important niche in the pharmaceutical industry. This chart reflects the overall dynamics of the orphan disease sector, where a high unmet need can lead to commercial success for a blockbuster drug.
Overall market profit
Mirum Pharmaceuticals specializes in drugs for rare liver diseases. Demand for its medications is driven by patient needs, not the economic cycle. However, the overall market conditions, as reflected in this chart, influence investor sentiment and the valuation of biotech companies.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Mirum Pharmaceuticals
Mirum Pharmaceuticals specializes in developing drugs to treat rare liver diseases, particularly in children. The company addresses complex medical problems where alternatives are scarce. This chart displays the analyst consensus forecast, which essentially estimates the commercial potential of its niche drugs and future profitability.
%20profit%20of%20the%20company%20Mirum%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Mirum-Pharmaceuticals&v=1772513805186 "Graph of future (projected) profit of the company Mirum Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Pharma liver
Mirum Pharmaceuticals specializes in developing drugs to treat rare liver diseases, particularly in children. The company brings life-saving medications to market for patients with limited treatment options. This chart shows profitability forecasts for the pharmaceutical sector, providing context for assessing the potential of companies operating in the orphan disease niche.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-liver&v=1772513805189 "Graph of future (predicted) profits of companies in a market segment - Pharma liver")
Future (predicted) profit of the market as a whole
Mirum Pharmaceuticals is a biotech company focused on rare liver diseases. Its value is determined solely by its success in drug development and commercialization. This business exists in its own world of scientific discoveries and clinical data, and its prospects are in no way tied to the overall corporate profit forecast presented in the chart.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513805194 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Mirum Pharmaceuticals
Mirum Pharmaceuticals develops drugs to treat rare liver diseases. This chart shows how the market values its highly specialized drugs. The ratio reflects the high cost of orphan drugs and the potential of its research and development in this niche.
P/S market segment - Pharma liver
Mirum Pharmaceuticals is a biopharmaceutical company specializing in the development and commercialization of drugs for rare liver diseases. This chart reflects the average revenue estimate in the biotech sector. It allows one to estimate the premium investors are willing to pay for Mirum's drugs, which target unmet medical needs, and their potential revenue.
P/S of the market as a whole
Mirum Pharmaceuticals specializes in the development and commercialization of drugs for the treatment of rare liver diseases, particularly in children. The company solves complex medical problems for small groups of patients. This chart provides a general revenue metric that can be used to assess how the market values biotech companies focused on orphan diseases.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Mirum Pharmaceuticals
Mirum Pharmaceuticals specializes in the development and commercialization of drugs for the treatment of rare liver diseases, particularly in children. This chart reflects the high investor expectations for future sales of its drugs. This valuation is based on the potential of its drugs to become standard treatments for patients with limited therapeutic options.
%20P%2FS%20Mirum%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Mirum-Pharmaceuticals&v=1772513805240 "The graph of the company's future (projected) P/S Mirum Pharmaceuticals")
Future (projected) P/S of the market segment - Pharma liver
Mirum Pharmaceuticals is a biopharmaceutical company specializing in developing treatments for rare liver diseases. Its success depends on the commercialization of niche but vital drugs. This chart compares market expectations for future sales of its drugs with those for the orphan drug sector.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20liver&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-liver&v=1772513805243 "Future (projected) P/S market segment graph - Pharma liver")
Future (projected) P/S of the market as a whole
Mirum Pharmaceuticals specializes in developing drugs for rare liver diseases. This chart, reflecting overall market sentiment, influences the investment climate in the biotech sector. During periods of optimism, investors are more inclined to fund companies operating in niche and risky areas, believing in the potential of their unique developments, which is critical for Mirum.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513805260 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Mirum Pharmaceuticals
Mirum Pharmaceuticals specializes in the development and commercialization of drugs for the treatment of rare liver diseases, particularly in children. This chart shows the revenue from sales of its approved drugs. The growth reflects the successful launch of life-saving drugs and the satisfaction of previously unmet medical needs in patients.
Sales of companies in the market segment - Pharma liver
Mirum Pharmaceuticals is a biopharmaceutical company specializing in the development and commercialization of drugs for the treatment of rare liver diseases. Its financial performance depends on the success of specific drugs. This chart shows the revenue from one of its leading drugs, allowing one to assess its market acceptance and commercial potential.
Overall market sales
Mirum Pharmaceuticals specializes in developing drugs for rare liver diseases. The company's success depends on regulatory approval and the introduction of its drugs into clinical practice, rather than on general economic trends. Mirum exemplifies how biotechnology creates value by solving specific yet critical medical problems.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Mirum Pharmaceuticals
Mirum Pharmaceuticals is a biopharmaceutical company specializing in the development of treatments for rare liver diseases in children and adults. Its future sales forecast reflects market expectations for the commercial success of its drugs. It shows how analysts assess the demand for its therapy and its potential to expand its indications.
%20sales%20of%20the%20company%20Mirum%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Mirum-Pharmaceuticals&v=1772513805340 "Schedule of future (projected) sales of the company Mirum Pharmaceuticals")
Future (projected) sales of companies in the market segment - Pharma liver
Mirum Pharmaceuticals specializes in developing drugs for rare liver diseases. This chart shows revenue expectations for the niche pharmaceutical sector. It reflects analysts' views on the potential of new treatments and the speed of their adoption by the medical community, which determines growth prospects for the entire field.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-liver&v=1772513805376 "Schedule of future (projected) sales of companies in the market segment - Pharma liver")
Future (projected) sales of the market as a whole
Mirum Pharmaceuticals develops drugs to treat rare liver diseases. The company's success depends on investments in biotechnology and the healthcare system's ability to afford expensive innovative drugs. This chart of overall sales forecasts reflects the overall economic situation, which influences these factors.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513805448 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Mirum Pharmaceuticals
Mirum Pharmaceuticals is a biopharmaceutical company specializing in the development and commercialization of drugs for the treatment of rare liver diseases. This chart shows how revenue from approved drugs compares with ongoing high R&D expenditures, driving the company's bottom line.
Market segment marginality - Pharma liver
Mirum Pharmaceuticals specializes in the development and commercialization of drugs for the treatment of rare liver diseases, particularly in children. This focus on orphan diseases allows the company to operate in markets with limited competition. This chart illustrates how such a niche strategy can lead to high operating margins if the drugs are successful.
Market marginality as a whole
Mirum Pharmaceuticals specializes in developing drugs for rare liver diseases. The company's success depends on regulatory approval and commercialization of its products. This graph reflects the profitability of mature businesses, whereas MIRM's value is created by addressing unmet medical needs and the potential of its research and development.
Employees in the company, segment and market as a whole
Number of employees in the company Mirum Pharmaceuticals
Mirum Pharmaceuticals specializes in developing drugs for rare liver diseases. This chart shows the growth of its scientific and commercial teams. Increasing the team size, especially after drug approval, is a key step in bringing drugs to market and communicating them to physicians.
Share of the company's employees Mirum Pharmaceuticals within the market segment - Pharma liver
Mirum Pharmaceuticals specializes in treating rare liver diseases. Developing drugs for orphan diseases requires a focused team of highly qualified scientists and clinicians. This chart shows the company's talent pool in this narrow but critically important biopharmaceutical niche.
Number of employees in the market segment - Pharma liver
Mirum Pharmaceuticals is focused on developing drugs for rare liver diseases. This chart shows the workforce in this highly specialized pharmaceutical niche. The growing number of scientists in this field indicates increased investment in orphan diseases, creating the scientific and financial foundation for advancing Mirum's drugs through clinical trials.
Number of employees in the market as a whole
Mirum Pharmaceuticals develops drugs to treat rare liver diseases. For companies like these, the economic cycle is less important. However, a strong labor market, as shown in this chart, supports the reliability of the healthcare and insurance systems, which is critical for ensuring patient access to life-saving and expensive medications.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Mirum Pharmaceuticals (MIRM)
Mirum Pharmaceuticals is a biopharmaceutical company specializing in rare liver diseases. Its staff is small, but highly skilled. The extremely high market capitalization per employee, reflected in this chart, reflects the market's valuation not of its assets, but of its intellectual property and the potential of its drugs to change patients' lives.
%20of%20the%20company%20Mirum%20Pharmaceuticals%20(MIRM)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Mirum-Pharmaceuticals-MIRM&v=1772513805768 "Chart of market capitalization per employee (in thousands of dollars) of the company Mirum Pharmaceuticals (MIRM)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma liver
Mirum Pharma (MIRM) is a biotech focused on rare liver diseases. Its value comes from its R&D pipeline and its hopes for future blockbusters. This chart shows the (often volatile) market value the market assigns to each of its research scientists.
%20by%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-liver&v=1772513805800 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma liver")
Market capitalization per employee (in thousands of dollars) for the overall market
Mirum Pharmaceuticals specializes in developing drugs for rare liver diseases. This focus on orphan diseases allows a small team of scientists to create drugs with enormous market potential. The chart illustrates the high premium the market places on the company's intellectual capital and scientific breakthroughs.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513805826 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Mirum Pharmaceuticals (MIRM)
Mirum Pharmaceuticals is a biopharmaceutical company specializing in rare liver diseases. Their drugs (like Livmarli) target very specific patient groups. This chart demonstrates the effectiveness of their R&D and commercial strategy. It measures how successfully their small but focused team can develop and commercialize high-value drugs for orphan diseases.
%20Chart%20Mirum%20Pharmaceuticals%20(MIRM)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Mirum-Pharmaceuticals-MIRM&v=1772513805903 "Company Profit Per Employee (in thousands of dollars) Chart Mirum Pharmaceuticals (MIRM)")
Profit per employee (in thousands of dollars) in the market segment - Pharma liver
Mirum Pharmaceuticals (MIRM) is a biotech company focused on "rare" liver diseases. This chart shows the benchmark for "Pharma liver" (Biotech). In this R&D sector, the benchmark is either negative (at the R&D stage) or astronomically high. This is the "blockbuster business," where a single patent for an orphan drug generates billions.
%20in%20the%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-liver&v=1772513806036 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma liver")
Profit per employee (in thousands of dollars) for the market as a whole
Mirum Pharmaceuticals (MIRM) is a biopharmaceutical company specializing in developing treatments for rare liver diseases (cholestatic), primarily in children. This graph, showing average profit per employee, is important for biotech. It allows us to assess how much a sector where a handful of scientists can create a breakthrough drug outperforms the "average" labor efficiency.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513806118 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Mirum Pharmaceuticals (MIRM)
Mirum Pharmaceuticals specializes in treating rare liver diseases. This chart is an indicator of the commercial success of its drugs. Following approval, the growth in revenue per employee will demonstrate how a highly specialized product can generate significant revenue due to its high price and lack of competition.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Mirum-Pharmaceuticals-MIRM&v=1772513806126 "Sales chart per company employee Mirum Pharmaceuticals (MIRM)")
Sales per employee in the market segment - Pharma liver
Mirum Pharmaceuticals is a biopharmaceutical company specializing in the treatment of rare liver diseases, particularly in children. Their drugs target very specific patient groups. This chart shows revenue per employee. Comparison with the segment helps assess the effectiveness of their commercial model (focusing on rare diseases) and how their R&D converts into revenue.
Sales per employee for the market as a whole
Mirum Pharmaceuticals is a biopharmaceutical company specializing in rare (orphan) liver diseases in children. They already have approved drugs. This chart shows how effectively their small but highly specialized team (R&D, commercial) generates revenue from the sale of these vital, but very expensive, drugs.
Short shares by company, segment and market as a whole
Shares shorted by company Mirum Pharmaceuticals (MIRM)
Mirum Pharmaceuticals is a biopharmaceutical company specializing in rare liver diseases, particularly in children. Their success depends on one or two key drugs. Investors closely monitor sales and new research. This chart shows the percentage of skeptics who doubt the market potential of their drugs or fear competition.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Mirum-Pharmaceuticals-MIRM&v=1772513806182 "Short Shares Chart for the Company Mirum Pharmaceuticals (MIRM)")
Shares shorted by market segment - Pharma liver
Mirum Pharmaceuticals (MIRM) is a biopharmaceutical company specializing in rare liver diseases, particularly in children. Their drugs target bile acid metabolism. This chart shows the odds against the rare disease biotech sector, reflecting investor concerns about the market size or the success of drug commercialization.
Shares shorted by the overall market
Mirum (MIRM) is a biotech focused on rare liver diseases. This indicator (`Short_All`) is a mirror of market fear. When it rises, investors panic and dump risk, especially unprofitable biotechs dependent on financing. This pessimism, visible on the chart, threatens the capital needed by MIRM.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Mirum Pharmaceuticals (MIRM)
Mirum Pharmaceuticals is a biotech company focused on rare liver diseases. Its stock is volatile and dependent on R&D. This MIRM chart can surge above 70 on positive trial data or approvals. A range below 30 is often associated with research setbacks, regulatory delays, or funding concerns.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Mirum-Pharmaceuticals-MIRM&v=1772513806350 "RSI 14 indicator chart for the company's stock Mirum Pharmaceuticals (MIRM)")
RSI 14 Market Segment - Pharma liver
Mirum Pharmaceuticals is a biotech company specializing in the treatment of rare liver diseases. The RSI_14_Seg for the "Pharma liver" (biotech) segment shows the overall sentiment. The chart helps us understand: is MIRM's volatility a reaction to its clinical trials, or is the entire sector overheated (or oversold)?
RSI 14 for the overall market
Mirum Pharmaceuticals, a biotech focused on rare liver diseases, is critically dependent on this schedule. Its survival depends on funding R&D. During periods of market euphoria, investors are willing to invest in risky but breakthrough research. In times of panic, risk appetite vanishes, and companies burning through cash risk running out of funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast MIRM (Mirum Pharmaceuticals)
Mirum Pharmaceuticals is a biopharmaceutical company specializing in developing treatments for rare liver diseases, particularly in children. Their first drug has been approved for the treatment of cholestatic pruritus. This chart shows the average analyst estimate. Their target prices are based on the commercial success of this drug and the progress of other programs in development.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-MIRM-Mirum-Pharmaceuticals&v=1772513806427 "A chart showing analyst consensus forecasts for the expected stock price. MIRM (Mirum Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price MIRM (Mirum Pharmaceuticals)
Mirum Pharmaceuticals (MIRM) is a biopharmaceutical company focused on treating rare liver diseases in children and adults. This chart is a barometer of their R&D. It measures the gap between the price and the consensus target, reflecting the commercial potential analysts see in their portfolio of orphan (rare) disease drugs.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-MIRM-Mirum-Pharmaceuticals&v=1772513806477 "A chart showing the difference between the consensus forecast and the actual stock price. MIRM (Mirum Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Pharma liver
Mirum Pharmaceuticals is a biotech company focused on developing drugs to treat rare liver diseases in children and adults. This chart shows analysts' overall expectations for the liver pharma sector. It reflects whether experts believe R&D pipelines in this complex niche are successful.
Analysts' consensus forecast for the overall market share price
Mirum Pharmaceuticals is a biopharmaceutical company specializing in developing treatments for rare liver diseases, particularly in children. This chart shows the company's overall risk appetite. For Mirum, as a highly focused biotech, overall market optimism is important for raising capital, but the stock price primarily responds to clinical trial data and regulatory decisions.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Mirum Pharmaceuticals
Mirum Pharmaceuticals is a biotech company focused on treating rare (orphan) liver diseases, primarily in children. Their drugs (Livmarli, Cholbam) target cholestatic diseases. This chart evaluates their orphan drug strategy. It measures the commercial success of their approved drugs and the potential of their R&D pipeline in this highly specialized niche.
AKIMA Market Segment Index - Pharma liver
Mirum Pharma is a biotech focused on rare (orphan) liver diseases, particularly in children. Their drug (Livmarli) treats cholestatic pruritus (severe itching due to liver disease). This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does Mirum's ultra-niche (rare liver disease) strategy differentiate it from the average pharma company?
The AKIM Index for the overall market
Mirum is a biotech company focused on rare liver diseases, primarily in children. It's a high-risk scientific bet. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this speculative story, driven by trial news, compares to overall economic trends that influence risk appetite.
